ARDX Trade idea
05:13 Piper still sees 'substantial upside' in Ardelyx despite last week's rally
Piper Jaffray analyst Christopher Raymond says he still expects "substantial upside" in shares of Ardelyx even after last week's 43% move. While Amplify's more "real world" representation assuaged the key investor concern around tenapanor's adverse event-related discontinuations, the market still hasn't grasped tenapanor's full market potential in the renal setting, Raymond tells investors in a research note. Feedback from a recent nephrologist survey indicates "significant" awareness, interest and willingness to prescribe tenapanor, adds the analyst. He sees the drug's revenue potential "at well" over 11B in the U.S. alone. As such, Raymond continues to view his $15 target as a "more appropriate valuation" than current share levels. He maintains an Overweight rating on Ardelyx.
Piper Jaffray analyst Christopher Raymond says he still expects "substantial upside" in shares of Ardelyx even after last week's 43% move. While Amplify's more "real world" representation assuaged the key investor concern around tenapanor's adverse event-related discontinuations, the market still hasn't grasped tenapanor's full market potential in the renal setting, Raymond tells investors in a research note. Feedback from a recent nephrologist survey indicates "significant" awareness, interest and willingness to prescribe tenapanor, adds the analyst. He sees the drug's revenue potential "at well" over 11B in the U.S. alone. As such, Raymond continues to view his $15 target as a "more appropriate valuation" than current share levels. He maintains an Overweight rating on Ardelyx.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.